Qiagen QGEN

NYSE · Biological Products, (No Diagnostic Substances) · $10.8B
$49.56−0.38%Nov 18 close · Databento
Every report →
TradingView’s own chart and price feed. The page’s numbers are end-of-day closes.

Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.

The numbers

fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Market cap$10.8B
EV / True FCF28.8x
Revenue$2.1B +5.7%
True FCF (ex-SBC)$402.9M −10.5%
Rule of 4027.4%
ROIC8.8%
True FCF Yield3.7%
EPS, diluted$1.94 +424.3%
Modern Valuation (EOD)
Market Cap$10.8B
Enterprise Value$11.6B
EV / True FCF28.81
EV / FCF25.61
EV / Gross Profit8.93
EV / EBIT24.92
EV / Sales5.55
P / E (GAAP)25.40
P / FCF23.81
P / Oper. CF16.49
P / Book2.86
Owner & Cash Yields
True FCF Yield3.7%
FCF Yield4.2%
Owner Earn. Yield3.4%
Earnings Yield3.9%
Shareholder Yield+2.6%
Buyback Yield2.6%
Dividend Yield0.50%
Dividend / sh$0.25
Payout Ratio13%
FCF / sh$2.09
EPS (diluted)$1.94
Compounder & Returns
Rule of 4027.4%
ROIC8.8%
Cash ROIC (CROIC)9.9%
GP / Assets20.7%
ROE11.2%
ROA6.8%
Gross Margin62.2%
Oper. Margin22.3%
Net Margin20.3%
FCF Margin21.7%
True FCF Margin19.3%
Quality & Dilution
Cash Conversion107%
Accrual Ratio−3.7%
SBC % of FCF11.1%
SBC % of Rev2.4%
Reinvest. Rate31%
Sales Growth Y/Y+5.7%
Sales 3Y CAGR−0.8%
EPS Growth Y/Y+424.3%
FCF Growth Y/Y−10.5%
FCF 3Y CAGR−8.2%
Share Change Y/Y−2.6%
Balance Sheet & Scale
Revenue (FY)$2.1B
Gross Profit (FY)$1.3B
Oper. Income (FY)$465.9M
GAAP Net Income$424.9M
True FCF (ex-SBC)$402.9M
Cash & Equiv$839.0M
Total Debt$1.7B
Net Cash (Debt)$-815.4M
Net Cash % MCap−7.6%
Debt / FCF (yrs)3.6y
Current Ratio3.90216.92M sh
Price & Technicals (EOD)
Perf Week−1.47%
Perf Month+1.35%
Perf Quarter+10.38%
Perf Half Y+41.24%
Perf YTD+45.94%
SMA 20 Dist−1.40%$50.26
SMA 50 Dist+5.63%$46.92
SMA 100 Dist+11.46%$44.46
Window High−2.56%$50.86
Window Low+51.88%$32.63
RSI (14) · Vol56.17%v
Income Distribution & Cash Flow ConversionHow every dollar of QGEN revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
REVENUE · 100%$2.1BGROSS PROFIT · 62.2%$1.3BCOST OF REV · 37.8%$790.5MOPER. INCOME · 22.3%$465.9MOPEX · 39.9%$833.6MNET INCOME · 20.3%$424.9M
Where Every $100 of Revenue Goes (FY2025)
Cost of Revenue (COGS)$790.5M ($37.8 / $100)
Operating Expenses$833.6M ($39.9 / $100)
Tax & Non-Operating$41.0M ($2.0 / $100)
Net Profit Kept$424.9M ($20.3 / $100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2025)
GAAP Net Income$424.9M (20.3% margin)
Operating Cash Flow (OCF)$654.3M(31.3% of rev)
Less: Capital Expenditures−$201.0M(9.6% of rev)
Standard Free Cash Flow (FCF)$453.3M(21.7% margin)
Less: Stock-Based Comp (SBC)−$50.4M(11.1% of FCF)
True FCF (Owner Cash ex-SBC)$402.9M(19.3% of rev)

Operating leverage — margins

GrossOperatingNet
0%40%80%62%22%20%FY21FY22FY23FY24FY25
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)FY2021FY2022FY2023FY2024FY2025YoY Δ4Y CAGRTrend
Income Statement
Cost of Revenue (COGS)$800.8M$757.0M$731.6M$1.0B$790.5M−21.8%−0.3%
Total Operating Expenses$820.7M$853.1M$823.8M$869.6M$833.6M−4.1%+0.4%
Interest Expense$54.5M$58.4M$53.4M$43.8M$33.3M−24.1%−11.6%
Income Tax Expense$113.2M$89.4M$88.5M$37.6M$65.4M+74.1%−12.8%
Diluted Shares232.0M230.1M230.6M224.7M218.9M−2.6%−1.4%
Balance Sheet
Cash & Equivalents$880.5M$730.7M$668.1M$663.6M$839.0M+26.4%−1.2%
Inventory$327.5M$358.0M$398.4M$279.3M$301.9M+8.1%−2.0%
Total Current Assets$2.1B$2.4B$2.1B$2.0B$2.0B+1.8%−1.4%
Total Assets$6.1B$6.3B$6.1B$5.7B$6.3B+10.4%+0.5%
Total Current Liabilities$1.5B$974.5M$1.1B$1.0B$512.1M−50.9%−23.8%
Total Debt (Short + Long Term)$2.8B$2.3B$2.1B$1.9B$1.7B−14.9%−12.2%
Stockholders' Equity$3.1B$3.5B$3.8B$3.6B$3.8B+5.9%+5.1%
Net Cash / (Net Debt)$-1.9B$-1.5B$-1.4B$-1.3B$-815.4M+36.3%—
Invested Capital$5.0B$5.0B$5.2B$4.8B$4.6B−5.2%−2.1%
Cash Flow & Capital Allocation
Depreciation & Amortization (D&A)$214.9M$208.4M$205.3M$203.3M$193.7M−4.7%−2.6%
Stock-Based Compensation (SBC)$38.4M$49.5M$47.1M$43.6M$50.4M+15.5%+7.0%
Capital Expenditures (CapEx)$189.9M$129.2M$149.7M$167.2M$201.0M+20.3%+1.4%
True FCF (ex-SBC Owner Cash)$410.7M$536.5M$262.6M$462.8M$402.9M−12.9%−0.5%
Share Repurchases (Buybacks)$100.0M$0$0$292.1M$280.1M−4.1%+29.4%
Dividends Paid——$0$0$54.2M——

Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.

On the Wire

what QGEN did at the next close after each story

No Wire story has named QGEN yet.

The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.